Navigation Links
The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
Date:6/1/2009

DOYLESTOWN, Pa. June 1 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that IVS Associates, Inc., the inspector of election for Quigley's 2009 annual meeting of shareholders, issued its final report, showing that Ted Karkus' seven director nominees received a larger number of votes than Quigley's incumbent directors.

The Company also announced that despite the final voting results issued today by IVS, the final outcome of the director election remains uncertain. On May 19, 2009, one day before the Company's 2009 Annual Meeting, the Company announced it had uncovered an undisclosed financial arrangement between Karkus and the Company's Quigley Pharma, Inc. subsidiary COO, Dr. Richard A. Rosenbloom. Karkus had previously stated in sworn testimony that at no time did he have any financial arrangement with any employee of The Quigley Corporation. Since the Annual Meeting, the Company has learned that Dr. Rosenbloom may have also had undisclosed financial arrangements with one of Karkus' director nominees and with John Ligums, an alleged member of the Karkus Group.

On May 29, 2009, upon a motion by the Company detailing these recent developments, the District Court Judge in the United States District Court for the Eastern District of Pennsylvania ordered the Company to operate under a standstill agreement with respect to the composition of the Company's Board of Directors pending a Court hearing on the motion. The Company expects the motion will be heard by Friday, June 5, 2009.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

    CONTACT:

    Gerard M. Gleeson            Mark Harnett / Bob Marese
    The Quigley Corporation      MacKenzie Partners, Inc.
    Vice President, CFO          (212) 929-5500
    (215) 345-0919               Quigley@mackenziepartners.com

    Carl Hymans
    G. S. Schwartz & Co.
    212-725-4500
    carlh@schwartz.com


'/>"/>
SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
2. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
3. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
4. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
5. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
6. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
7. The Quigley Corporation Reports First Quarter 2009 Results
8. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
9. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
10. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
11. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... ... California Southern University has named Dr. Steven Beazley University President. ... a core faculty member, teaching master’s and doctoral courses in the university’s School of ... where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also has ...
(Date:1/16/2017)... ... 16, 2017 , ... With the Grand Opening Event planned for February 3, ... sports teams and the general public. Built in five months by Centerpoint, the 60,000 ... into basketball or pickleball courts. The space is also suitable for indoor soccer and ...
(Date:1/16/2017)... ... January 16, 2017 , ... As New York’s ... Victor Giamos, MD to their medical staff, according to eye surgeon, Jeffrey Martin, ... Eye Care, a division of SightMD. Dr. Giamos will practice primarily out of ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... their recent partnership with an innovator in the wheelchair accessibility industry, BraunAbility ... their dealer salespeople to sell wheelchair accessible vehicles. With this new incentive plan, ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Aesthetic Surgery Journal , the official journal of The American Society for Aesthetic ... retraction surgery. The procedure is designed to correct drooping, retracted lower eyelids, which ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)...  This report by Persistence Market Research examines ... the period 2016–2024. The primary objective of the ... to market opportunities in the global peripherally inserted ... the various dynamics that are expected to influence ... global peripherally inserted central catheters market over the ...
(Date:1/16/2017)... 2017   The Harrington Discovery Institute ... , has announced the 2017 recipients of ... of physician-scientists whose research shows promise to advance ... Discovery Institute – part of The Harrington Project ... in academic medicine: to advance early breakthroughs into ...
(Date:1/16/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Vital Signs Monitoring ... and Industry Forecast, 2014-2022", projects that the global vital signs ... and is expected to reach $5,491 million by 2022, growing ... North America was the leading regional market ...
Breaking Medicine Technology: